Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8846 |
High Similarity |
NPD3027 |
Phase 3 |
0.8788 |
High Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8788 |
High Similarity |
NPD1613 |
Approved |
0.8769 |
High Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8692 |
High Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8254 |
Intermediate Similarity |
NPD6671 |
Approved |
0.8106 |
Intermediate Similarity |
NPD4749 |
Approved |
0.8088 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.8082 |
Intermediate Similarity |
NPD1653 |
Approved |
0.808 |
Intermediate Similarity |
NPD228 |
Approved |
0.8074 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8054 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7987 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7956 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7955 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7923 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7883 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7868 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7868 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.782 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7815 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7794 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.776 |
Intermediate Similarity |
NPD290 |
Approved |
0.7744 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7734 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7712 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7704 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7704 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7698 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7692 |
Intermediate Similarity |
NPD7157 |
Approved |
0.763 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7597 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7595 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7595 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7595 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7571 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7568 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7556 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7556 |
Intermediate Similarity |
NPD3705 |
Approved |
0.754 |
Intermediate Similarity |
NPD968 |
Approved |
0.7538 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7518 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7516 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7467 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7465 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7465 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7453 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7448 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7448 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7445 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7419 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7415 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7407 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7391 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7389 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7386 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7386 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7365 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7364 |
Intermediate Similarity |
NPD4750 |
Phase 3 |
0.736 |
Intermediate Similarity |
NPD846 |
Approved |
0.736 |
Intermediate Similarity |
NPD291 |
Approved |
0.736 |
Intermediate Similarity |
NPD940 |
Approved |
0.7351 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7346 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7315 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7297 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7297 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7296 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7292 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7292 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7285 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7279 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7279 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7279 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7279 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7279 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7273 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7248 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7241 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7239 |
Intermediate Similarity |
NPD7340 |
Approved |
0.7233 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7231 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7231 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7222 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7219 |
Intermediate Similarity |
NPD1774 |
Approved |
0.7215 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7212 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7211 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.7208 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7206 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7205 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.72 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.72 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7197 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7197 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7192 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7181 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7179 |
Intermediate Similarity |
NPD37 |
Approved |
0.7178 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7172 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7172 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7171 |
Intermediate Similarity |
NPD1754 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7169 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7169 |
Intermediate Similarity |
NPD7549 |
Discontinued |
0.7162 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7154 |
Intermediate Similarity |
NPD9296 |
Approved |
0.7153 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7152 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7152 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7152 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7152 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD289 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7132 |
Intermediate Similarity |
NPD7534 |
Approved |
0.7132 |
Intermediate Similarity |
NPD7533 |
Approved |
0.7107 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7105 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7105 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7083 |
Intermediate Similarity |
NPD8053 |
Approved |
0.7083 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7075 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7075 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7075 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7071 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7063 |
Intermediate Similarity |
NPD596 |
Approved |
0.7063 |
Intermediate Similarity |
NPD600 |
Approved |
0.7059 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7055 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7051 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7048 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7042 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7039 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7037 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7034 |
Intermediate Similarity |
NPD840 |
Approved |
0.7034 |
Intermediate Similarity |
NPD839 |
Approved |
0.7034 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7034 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.7032 |
Intermediate Similarity |
NPD3686 |
Approved |
0.7032 |
Intermediate Similarity |
NPD3687 |
Approved |
0.7025 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7014 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7013 |
Intermediate Similarity |
NPD52 |
Approved |
0.7013 |
Intermediate Similarity |
NPD7527 |
Clinical (unspecified phase) |
0.7013 |
Intermediate Similarity |
NPD7526 |
Approved |
0.7012 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.6993 |
Remote Similarity |
NPD6799 |
Approved |
0.6993 |
Remote Similarity |
NPD9494 |
Approved |
0.6993 |
Remote Similarity |
NPD4357 |
Discontinued |
0.6987 |
Remote Similarity |
NPD3111 |
Phase 1 |
0.6987 |
Remote Similarity |
NPD4005 |
Discontinued |
0.6986 |
Remote Similarity |
NPD2238 |
Phase 2 |
0.6981 |
Remote Similarity |
NPD2560 |
Approved |
0.6981 |
Remote Similarity |
NPD2563 |
Approved |
0.698 |
Remote Similarity |
NPD1551 |
Phase 2 |
0.698 |
Remote Similarity |
NPD2161 |
Phase 2 |
0.698 |
Remote Similarity |
NPD6032 |
Approved |
0.698 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6975 |
Remote Similarity |
NPD1247 |
Approved |
0.6966 |
Remote Similarity |
NPD3144 |
Approved |
0.6966 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6966 |
Remote Similarity |
NPD3145 |
Approved |
0.696 |
Remote Similarity |
NPD844 |
Approved |
0.6959 |
Remote Similarity |
NPD7906 |
Approved |
0.6954 |
Remote Similarity |
NPD4236 |
Phase 3 |
0.6954 |
Remote Similarity |
NPD3060 |
Approved |
0.6954 |
Remote Similarity |
NPD4237 |
Approved |
0.694 |
Remote Similarity |
NPD821 |
Approved |
0.6939 |
Remote Similarity |
NPD5735 |
Approved |
0.6934 |
Remote Similarity |
NPD1408 |
Clinical (unspecified phase) |
0.6934 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6933 |
Remote Similarity |
NPD6004 |
Phase 3 |
0.6933 |
Remote Similarity |
NPD6002 |
Phase 3 |
0.6933 |
Remote Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.6933 |
Remote Similarity |
NPD6005 |
Phase 3 |
0.6933 |
Remote Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.6929 |
Remote Similarity |
NPD1611 |
Approved |
0.6923 |
Remote Similarity |
NPD3690 |
Phase 2 |
0.6923 |
Remote Similarity |
NPD3691 |
Phase 2 |
0.6918 |
Remote Similarity |
NPD5773 |
Approved |
0.6918 |
Remote Similarity |
NPD5772 |
Approved |
0.6918 |
Remote Similarity |
NPD7819 |
Suspended |
0.6913 |
Remote Similarity |
NPD5960 |
Phase 3 |
0.6913 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6913 |
Remote Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.6913 |
Remote Similarity |
NPD5588 |
Approved |
0.6913 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6913
|
Remote Similarity |
NPD6028 |
Clinical (unspecified phase) |